Previous 10 | Next 10 |
ANI Pharmaceuticals ( NASDAQ: ANIP ) gained ~3% in the morning hours Wednesday, marking the biggest intraday gain since late January, after Guggenheim launched its coverage with a Buy recommendation citing the company’s hormonal autoimmune therapy Cortrophin Gel. Cortrophin...
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its fourth quarter and full year 2022 financial results on Thursday, March 9, 2023, prior to market open. Nikhil Lalwani, President and Chief Executive O...
Summary Results from three major testosterone trials expected in 2023, including the largest testosterone cardiovascular safety/efficacy trials for men and women. AbbVie led Androgel 1.62% 5,246-participant cardiovascular safety trial is also measuring efficacy for dysthymia, clinical f...
ANI Pharmaceuticals ( NASDAQ: ANIP ) on Monday said it had got U.S. Food and Drug Administration (FDA) approval for its generic version of the drug carnitor. The FDA approval was for ANIP's levocarnitine tablets, 330 mg. ANIP's levocarnitine tablets are a generic version of the dr...
ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Levocarnitine Tablets USP, 330 mg. ANI’s Levocarnitine Tablets are the generic version of ...
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that the Company received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Fluoxetine Oral Solution, USP 20 mg/5 mL. ANI&...
ANI Pharmaceuticals ( NASDAQ: ANIP ) said the U.S. Food and Drug Administration (FDA) approved its generic antibiotic trimethoprim tablets USP, 100 mg. Trimethoprim is an antibiotic used to treat bacterial infections. "As we continue to focus on bringing niche...
ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Trimethoprim Tablets USP, 100 mg. ANI’s Trimethoprim Tablets are the generic ver...
ANI Pharmaceuticals, Inc. (ANIP) Q3 2022 Earnings Conference Call November 09, 2022, 08:00 AM ET Company Participants Judy DiClemente - IR Nikhil Lalwani - President and CEO Steve Carey - CFO Christopher Mutz - Head, Rare Disease Conference Call Partici...
ANI Pharmaceuticals press release ( NASDAQ: ANIP ): Q3 Non-GAAP EPS of $0.64 beats by $0.09 . Revenue of $83.8M (+61.0% Y/Y) beats by $5.44M . Adjusted non-GAAP EBITDA of $19.6M. Reiterates total Company net revenue guidance of $295 million to $315 million ...
News, Short Squeeze, Breakout and More Instantly...
ANI Pharmaceuticals Inc. Company Name:
ANIP Stock Symbol:
NASDAQ Market:
ANI Pharmaceuticals Inc. Website:
PRINCETON, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) and launched Naproxen Delayed-Release Tablets, USP....
PRINCETON, N.J., June 25, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that its Chief Executive Officer, Nikhil Lalwani, has been named an Ernst & Young LLP (EY US) Entrepreneur Of The Year ® 2024 New Jersey Award winner. Entr...
2024-06-24 08:08:29 ET Alimera Sciences Inc (NASDAQ: ALIM) rallied a whopping 75% in premarket today after ANI Pharmaceuticals Inc (NASDAQ: ANIP) said it will buy the Alpharetta, Georgia based company for about $381 million. ANI shares are roughly flat at writing. Alimera Sc...